The primary strategic areas of the Liverpool ECMC are pancreatic cancer and haemato-oncology, with expertise in cancer biology and pharmacology to develop novel biomarkers of efficacy, resistance and drug safety.
Other areas of focus supported by local expertise are breast cancer brain metastases, hepatobiliary cancers and head and neck cancers.
The Liverpool ECMC is a collaboration between the University of Liverpool (Liverpool Clinical Trials Centre and Good Clinical Practice Laboratory Facility) and The Clatterbridge Cancer Centre NHS Foundation Trust. ECMC status was awarded to Liverpool in 2017 and is funded by Cancer Research UK and the National Institute for Health Research.
Aims
- Facilitate the transition of new drugs/combinations from early to late phase clinical trials with integrated biomarker development and to develop stratified approaches to more effective use of existing drugs
- Improve access and recruitment to early phase trials for cancer patients in Merseyside and Cheshire
- Increase Liverpool Clinical Trials Centre led early phase clinical trials
- Partner with the ECMC Network to deliver ECMC trials in the region.
Back to: Institute of Systems, Molecular and Integrative Biology